Isracann Biosciences Stock Market Outlook
Roughly 67% of Isracann Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Isracann Biosciences pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Isracann Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Isracann Biosciences stock news signals to limit their universe of possible portfolio assets.
Comfort Level 33
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Isracann Biosciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Isracann Biosciences.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Isracann Biosciences is 'Strong Sell'. Macroaxis provides Isracann Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ISCNF positions.
Execute Isracann Biosciences Advice
The Isracann recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Isracann Biosciences. Macroaxis does not own or have any residual interests in Isracann Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Isracann Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
For the selected time horizon Isracann Biosciences has a Return On Equity of -2.53, Return On Asset of -0.35, Current Valuation of 2.16 M, Shares Outstanding of 175.99 M, Shares Owned By Insiders of 0.50 % and Price To Book of 9.57 XWe provide advice to complement the regular expert consensus on Isracann Biosciences. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Isracann Biosciences is not overpriced, please check out all Isracann Biosciences fundamentals, including its current ratio, as well as the relationship between the number of employees and z score . As Isracann Biosciences appears to be a penny stock we also urge to confirm its debt to equity numbers.
Isracann Biosciences Trading Alerts and Improvement Suggestions
| Isracann Biosciences generated a negative expected return over the last 90 days | |
| Isracann Biosciences has some characteristics of a very speculative penny stock | |
| Isracann Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Isracann Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Isracann Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Isracann Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Isracann to invest in growth at high rates of return. When we think about Isracann Biosciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (4.69 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Isracann Biosciences has accumulated about 310.61 K in cash with (1.75 M) of positive cash flow from operations. |
Isracann Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Isracann Biosciences or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Isracann Biosciences' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Isracann pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Isracann Biosciences Volatility Alert
At this time Isracann Biosciences exhibits very low volatility. You can indeed make money on Isracann instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Isracann Biosciences Fundamentals Vs Peers
Comparing Isracann Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Isracann Biosciences' direct or indirect competition across all of the common fundamentals between Isracann Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Isracann Biosciences or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Isracann Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Isracann Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Isracann Biosciences to competition |
| Fundamentals | Isracann Biosciences | Peer Average |
| Return On Equity | -2.53 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Current Valuation | 2.16 M | 16.62 B |
| Shares Outstanding | 175.99 M | 571.82 M |
| Shares Owned By Insiders | 0.50 % | 10.09 % |
| Price To Book | 9.57 X | 9.51 X |
| Price To Sales | 8.83 X | 11.42 X |
| EBITDA | (4.64 M) | 3.9 B |
| Net Income | (4.69 M) | 570.98 M |
| Cash And Equivalents | 310.61 K | 2.7 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 0.76 X | 2.16 X |
| Book Value Per Share | 0 X | 1.93 K |
| Cash Flow From Operations | (1.75 M) | 971.22 M |
| Earnings Per Share | (0.13) X | 3.12 X |
| Number Of Employees | 4 | 18.84 K |
| Beta | 0.12 | -0.15 |
| Market Capitalization | 2.45 M | 19.03 B |
| Total Asset | 4.09 M | 29.47 B |
| Z Score | -3.3 | 8.72 |
| Net Asset | 4.09 M |
About Isracann Biosciences Buy or Sell Advice
When is the right time to buy or sell Isracann Biosciences? Buying financial instruments such as Isracann Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Isracann Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency Thematic Idea Now
Cryptocurrency
Dynamically computed list of top cryptocurrencies sorted bymarket capitalization. The Cryptocurrency theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Isracann Pink Sheet
Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.